Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CDC25A | P30304 | 1/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2640777 | 0.84 | L3MBTL1 (0.39) | ALDH1A1HPGDL3MBTL1HSP90AA1KMT2A | |
| SCHEMBL30786800 | 0.81 | DGKA (0.53) | ALDH1A1HPGDKMT2AEPHX2 | |
| SCHEMBL29981513 | 0.81 | DGKA (0.53) | ALDH1A1HPGDKMT2AEPHX2 | |
| SCHEMBL30786801 | 0.81 | DGKA (0.53) | ALDH1A1HPGDKMT2AEPHX2 | |
| SCHEMBL133636 | 0.79 | ALDH1A1 (0.59) | ALDH1A1KDM4EHPGDL3MBTL1KMT2A | |
| SCHEMBL29079457 | 0.78 | ALDH1A1 (0.60) | ALDH1A1MAPTKDM4ESMN1; SMN2HPGD | |
| SCHEMBL2499648 | 0.78 | ALDH1A1 (0.49) | ALDH1A1MAPTKDM4ERAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28136732 | 0.77 | ALDH1A1 (0.58) | ALDH1A1KDM4EHPGDL3MBTL1KMT2A | |
| Water SCHEMBL27569528 | 0.77 | ALDH1A1 (0.58) | ALDH1A1KDM4EHPGDL3MBTL1KMT2A | |
| SCHEMBL4206900 | 0.77 | DGKA (0.49) | ALDH1A1HPGDKMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034571-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2025-01-30 | — | — | US | disclosed |
| US-12129467-B2 | Non-liposomal systems for nucleic acid delivery | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-10-29 | — | — | US | disclosed |
| US-20240182895-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-06 | — | — | US | disclosed |
| US-20240035030-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-02-01 | — | — | US | disclosed |
| US-11718852-B2 | Non-liposomal systems for nucleic acid delivery | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-08 | — | — | US | disclosed |
| US-20210207140-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-07-08 | — | — | US | disclosed |
| EP-2569276-B1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2021-02-24 | — | — | EP | disclosed |
| US-20200282060-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-09-10 | — | — | US | disclosed |
| US-20190032051-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2019-01-31 | — | — | US | disclosed |
| US-20170260523-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2017-09-14 | — | — | US | disclosed |
| US-9518272-B2 | Non-liposomal systems for nucleic acid delivery | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2016-12-13 | — | — | US | disclosed |
| US-20160251681-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2016-09-01 | — | — | US | disclosed |
| US-9404127-B2 | Non-liposomal systems for nucleic acid delivery | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2016-08-02 | — | — | US | disclosed |
| US-20160032320-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2016-02-04 | — | — | US | disclosed |
| US-9006417-B2 | Non-liposomal systems for nucleic acid delivery | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2015-04-14 | — | — | US | disclosed |
| US-8865675-B2 | Compositions and methods for silencing apolipoprotein B | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2014-10-21 | — | — | US | disclosed |
| US-20130303587-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2013-11-14 | — | — | US | disclosed |
| US-20130123338-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2013-05-16 | — | — | US | disclosed |
| US-20130123339-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | PROTIVA BIOTHERAPEUTICS INC (CA) | 2013-05-16 | — | — | US | disclosed |
| WO-2012000104-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190032051-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | ALDH1A1 3573/4885MAPT 3980/4885KDM4E 3751/4885 |
| US-20170260523-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | ALDH1A1 3573/4885MAPT 3980/4885KDM4E 3751/4885 |
| US-20160251681-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | ALDH1A1 3573/4885MAPT 3980/4885KDM4E 3751/4885 |
| US-20240182895-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | ALDH1A1 3573/4885MAPT 3980/4885KDM4E 3751/4885 |
| US-20130123338-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PLIN3, CETP, LDLR | ALDH1A1 4646/4885MAPT 4267/4885KDM4E 4157/4885 |
| US-20250034571-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | ALDH1A1 3573/4885MAPT 3980/4885KDM4E 3751/4885 |
| US-20210207140-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | ALDH1A1 3573/4885MAPT 3980/4885KDM4E 3751/4885 |
| US-20160032320-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | ALDH1A1 3573/4885MAPT 3980/4885KDM4E 3751/4885 |
| US-20200282060-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PLIN3, CETP, LDLR | ALDH1A1 4646/4885MAPT 4267/4885KDM4E 4157/4885 |
| US-20240035030-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | ALDH1A1 3573/4885MAPT 3980/4885KDM4E 3751/4885 |
| US-20130123339-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | APOB, LDLR, APOL1 | ALDH1A1 3439/4885MAPT 3899/4885KDM4E 4030/4885 |
| US-12129467-B2 | Non-liposomal systems for nucleic acid delivery | SNRPE, NPC1L1, LIPA | ALDH1A1 3573/4885MAPT 3980/4885KDM4E 3751/4885 |
| US-20130303587-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | ALDH1A1 3573/4885MAPT 3980/4885KDM4E 3751/4885 |
| US-11718852-B2 | Non-liposomal systems for nucleic acid delivery | SNRPE, NPC1L1, LIPA | ALDH1A1 3573/4885MAPT 3980/4885KDM4E 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.